Neoadjuvant tyrosine kinase inhibitors in rectal gastrointestinal stromal tumours: a provision for enhanced oncological and functional outcomes.
Zachary Zihui YongJolene Si Min WongMelissa Ching Ching TeoClaramae Shulyn ChiaChin-Ann Johnny OngMohamad FaridGrace Hwei Ching TanPublished in: International journal of clinical oncology (2021)
Neoadjuvant TKI has the benefit of downsizing unresectable rectal GIST to benefit from sphincter-sparing procedure and also confers protection against local recurrence and improves overall survival.